This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
IF PRESENT FINDINGS hold up, US physicians should by early next year have a safe and effective vaccine against varicella.
Trials with production lots of the vaccine are under way. A license application will be submitted to the Food and Drug Administration, Rockville, Md, probably in the next two or three months.
Meanwhile, the manufacturer is studying incorporation of the varicella vaccine into the measles-mumps-rubella combination. When this is licensed, investigators say, it should simplify the pediatric immunization schedule.The varicella vaccine is an attenuated live virus agent, cultivated for 31 passages on MRC-5 cells, a human diploid line. To date, more than 9000 children and 2000 adolescents and adults in a number of studies have been immunized with the agent with an overall efficacy greater than 80%.Some 95% of vaccinees have demonstrated protective antibody titers for up to six years. The vaccine is given by subcutaneous injection
Marwick C. Varicella Vaccine Expected to Be Ready by 1993. JAMA. 1992;268(7):851-852. doi:10.1001/jama.1992.03490070029011